Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ultragenyx Pharmaceutical (RARE)
NASDAQ:RARE
RESEARCH TOOLSreports
Holding RARE?
Track your performance easily
See the Price Targets and Ratings of:
RARE Analyst Ratings
Strong Buy
16 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
RARE Stock 12 Month Forecast
Average Price Target
$92.53
▲(106.77% Upside)
| Highest Price Target$135.00 | Average Price Target$92.53 | Lowest Price Target$48.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Evercore ISI
Assigned
11/12/24
TD Cowen
Reiterated
11/11/24
Canaccord Genuity
Reiterated
11/11/24
Stifel Nicolaus
Reiterated
11/11/24
Leerink Partners
Reiterated
11/09/24
H.C. Wainwright
Reiterated
11/06/24
Morgan Stanley
Reiterated
11/06/24
Wedbush
Reiterated
11/06/24
Barclays
Reiterated
11/06/24
Piper Sandler
Assigned
11/06/24
Bank of America Securities
―
Buy
―
Reiterated
11/06/24
Bank of America Securities Sticks to Their Buy Rating for Ultragenyx Pharmaceutical (RARE)
Robert W. Baird
$72
Buy
60.89%
Upside
Reiterated
11/06/24
Analysts Conflicted on These Healthcare Names: Ultragenyx Pharmaceutical (NASDAQ: RARE), Henry Schein (NASDAQ: HSIC) and McKesson (NYSE: MCK)
Cantor Fitzgerald
$116
Buy
159.22%
Upside
Reiterated
11/05/24
Ultragenyx Pharmaceutical (RARE) Receives a Buy from Cantor Fitzgerald
Wells Fargo
$75
Buy
67.60%
Upside
Reiterated
11/05/24
Promising Developments and Strategic Progress Drive Buy Recommendation for Ultragenyx Pharmaceutical
RBC Capital
$77
Buy
72.07%
Upside
Reiterated
11/05/24
RBC Capital Sticks to Their Buy Rating for Ultragenyx Pharmaceutical (RARE)
Best Analysts Covering Ultragenyx Pharmaceutical
Which Analyst Should I Follow If I Want to Buy RARE and Sell After:
1 Month
xxx
Success Rate
14/24 ratings generated profit
Average Return
+1.85%
reiterated a xxx
rating 18 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 58.33% of your transactions generating a profit, with an average return of +1.85% per trade.
3 Months
xxx
Success Rate
11/18 ratings generated profit
Average Return
+4.07%
reiterated a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 61.11% of your transactions generating a profit, with an average return of +4.07% per trade.
1 Year
Success Rate
12/18 ratings generated profit
Average Return
+3.67%
reiterated a buy rating 5 months ago
Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +3.67% per trade.
2 Years
xxx
Success Rate
16/22 ratings generated profit
Average Return
+31.30%
reiterated a xxx
rating 13 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 72.73% of your transactions generating a profit, with an average return of +31.30% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
RARE Analyst Recommendation Trends
Rating
Jul 24
Aug 24
Sep 24
Oct 24
Nov 24
Strong Buy
45
31
20
13
15
Buy
11
12
14
15
17
Hold
3
2
2
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
59
45
36
29
33
Each month's total comprises the sum of three months' worth of ratings.
RARE Financial Forecast
RARE Stock Forecast FAQ
What is RARE’s average 12-month price target, according to analysts?
Based on analyst ratings, Ultragenyx Pharmaceutical’s 12-month average price target is $92.53.
What is RARE’s upside potential, based on the analysts’ average price target?
Ultragenyx Pharmaceutical has 106.77% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is RARE a Buy, Sell or Hold?
Ultragenyx Pharmaceutical has a consensus rating of Strong Buy which is based on 16 buy ratings, 1 hold ratings and 0 sell ratings.
What is Ultragenyx Pharmaceutical’s price target?
The average price target for Ultragenyx Pharmaceutical is $92.53. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $135.00 ,the lowest forecast is $48.00. The average price target represents 106.77% Increase from the current price of $44.75.
The highest analyst price target is $135.00 ,the lowest forecast is $48.00. The average price target represents 106.77% Increase from the current price of $44.75.
What do analysts say about Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical’s analyst rating consensus is a Strong Buy. This is based on the ratings of 17 Wall Streets Analysts.
How can I buy shares of RARE?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.